Bioforce Nanosciences Holdings, INC 10-Q quarterly reports

BioForce Nanosciences Holdings, Inc. reported its Q2 2026 financial results, highlighting a strategic pivot to the oil and gas industry and a net income of $238,682 for the quarter, contrasting with a net loss in the prior year.

BioForce Nanosciences Holdings, Inc. reported zero revenue for the first quarter of 2026, continuing its transition to a nutritional supplement business while facing ongoing operational challenges and a going concern warning.

BioForce Nanosciences Holdings, Inc. reported a significant net loss for the nine months ended September 30, 2025, with no revenue generated from its nutritional supplement business.

BioForce Nanosciences Holdings, Inc. reported a significant net loss of over $1 million for the first half of 2025, driven by a liability settlement, with no sales revenue generated.

BioForce Nanosciences Holdings reports no sales revenue and a substantial net loss for the quarter ended March 31, 2025, primarily due to a loss on liability settlement.

BioForce Nanosciences Holdings reported no revenue and a net loss for the third quarter of 2024, with ongoing concerns about its ability to continue as a going concern.

BioForce Nanosciences Holdings reported no revenue for the second quarter of 2024 and continues to face significant financial challenges.

BioForce Nanosciences Holdings reported a net loss of $130,813 for the first quarter of 2024, with no revenue generated from product sales.